Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Platinum International Health Care Fund","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Haema Logi X Raises $10 Million to Advance Multiple Myeloma Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HaemaLogiX To Present Final Data from Anti-KMA CAR-T Preclinical Studies At AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by HaemaLogiX

    Menu

    HaemaLogiX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              HaemaLogiX

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial

              Details:

              MDX-1097 (kappamab) targets a receptor called Kappa Myeloma Antigen (KMA) found only on the surface of myeloma cells in in combination with lenalidomide and dexamethasone in kappa-type multiple myeloma patients who had relapsed or become refractory to other treatment options.

              Lead Product(s): KappaMab,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology Product Name: MDX-1097

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HaemaLogiX

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HaemaLogiX To Present Final Data from Anti-KMA CAR-T Preclinical Studies At AACR

              Details:

              Anti-KMA CAR-T is a myeloma-specific antigen not found on normal cells. It has completed preclinical studies and is being developed to treat kappa-type multiple myeloma.

              Lead Product(s): Anti-KMA CAR-T Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              HaemaLogiX

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Haema Logi X Raises $10 Million to Advance Multiple Myeloma Treatments

              Details:

              The funds raised under the placement will directly support manufacturing of the next batch of the Kappa antibody, MDX-1097 plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.

              Lead Product(s): KappaMab,Dexamethasone,Lenalidomide

              Therapeutic Area: Oncology Product Name: MDX-1097

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Platinum International Health Care Fund

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Financing September 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY